OncoDxRx’s Post

The reality of today’s precision medicine is only 10% of cancer patients experience a clinical benefit from treatments matched to tumor DNA mutations (via biomarker testing). OncoDxRx's mission is to build a personalized guide of the most effective drugs for every cancer patient. OncoDxRx’s one-of-a-kind PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) works by testing tumor gene activities from a patient’s own blood before administering treatment, tailoring therapies that are most likely to benefit the patient while minimizing waiting time, cost and ineffective drugs. Other than DNA mutations, PGA takes a different approach to personalizing treatments. The technology takes a sample of a patient’s blood, analyzes patient-unique gene expression signature, searches and maps over 700 drugs (approved, investigational or in clinical trials). In this process, the scientists look for the medications that the patient has a high likelihood to respond to. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

Engineered Plasma B Cells Can Provide Long-Lasting Drug Production In Vivo Researchers have shown that engineered human plasma B cells (ePCs) can effectively treat leukemia in a humanized animal model. This milestone achievement opens up new possibilities for treating cancer, autoimmune disorders, and protein deficiency diseases. The study, published in Molecular Therapy, focused on developing ePCs that produce bispecific antibodies to target B-cell acute lymphoblastic leukemia (B-ALL). These engineered cells offer a potential solution to the limitations of current treatments like blinatumomab, which require continuous high-dose intravenous infusions. This proof-of-concept study is the first of many applications of engineered plasma B cells, and eventually will lead to a single-shot therapeutic. The longevity of these cells, potentially exceeding 10 years, makes them an attractive option for long-term drug delivery. The researchers successfully created ePCs capable of secreting anti-CD19 bispecific antibodies, which demonstrated antitumor activity in immunodeficient mice with acute lymphoblastic leukemia patient-derived xenografts. Remarkably, the concentration of bispecifics in serum one month after cell delivery was comparable to levels observed in patients receiving continuous blinatumomab infusion. These cells effectively eliminated tumors to a comparable extent as the clinical drug. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx #genomics #NGS #CRISPR #gene #geneexpression #artificialintelligence #machinelearning #sequencing

🌟 𝙀𝙭𝙘𝙞𝙩𝙞𝙣𝙜 𝘿𝙚𝙫𝙚𝙡𝙤𝙥𝙢𝙚𝙣𝙩𝙨 𝙞𝙣 𝙩𝙝𝙚 #𝙎𝙢𝙖𝙡𝙡 #𝙈𝙤𝙡𝙚𝙘𝙪𝙡𝙚 #𝙏𝙖𝙧𝙜𝙚𝙩𝙚𝙙 #𝘾𝙖𝙣𝙘𝙚𝙧 #𝙏𝙝𝙚𝙧𝙖𝙥𝙮 #𝙈𝙖𝙧𝙠𝙚𝙩! 🚀 𝙂𝙚𝙩 𝙁𝙧𝙚𝙚 𝙎𝙖𝙢𝙥𝙡𝙚 𝙤𝙛 𝘾𝙤𝙢𝙥𝙧𝙚𝙝𝙚𝙣𝙨𝙞𝙫𝙚 𝙂𝙪𝙞𝙙𝙚:https://lnkd.in/gBXvyEv3 📊 The Small Molecule Targeted Cancer Therapy Market is undergoing dynamic changes, with groundbreaking advancements reshaping the landscape. Here's a fresh take on the latest report highlights: 🔬 Innovative Treatments: Revolutionary small molecule therapies are revolutionizing cancer treatment paradigms, offering precise targeting of cancer cells with minimal side effects. 💡 Emerging Technologies: The market is abuzz with the emergence of cutting-edge technologies, such as precision medicine and gene editing, driving the development of highly effective targeted therapies. 💰 Market Expansion: With increasing investment and R&D activities, the Small Molecule Targeted Cancer Therapy Market is experiencing exponential growth, presenting lucrative opportunities for stakeholders. 🌎 Global Reach: These advancements are not confined to a specific region but are making waves globally, transforming the way cancer is treated and managed on a worldwide scale. 👩⚕️ Patient-Centered Care: Amidst these innovations, a strong emphasis on patient-centered care remains pivotal, ensuring that advancements translate into improved outcomes and quality of life for cancer patients. Key Players: Roche Novartis Pfizer Bristol Myers Squibb Squibb Merck Group. AstraZeneca Takeda Pharmaceuticals (formerly Nycomed) Eli Lilly and Company Johnson & Johnson AbbVie Ipsen 💪 #CancerTherapy #PrecisionMedicine #MedicalInnovation #small #molecule #cancer #therapy #market

Switzerland is a biotech powerhouse, with established players in every stage along the way, from education to manufacturing going through research and development. Taking into account the country’s success last year, Switzerland is undoubtedly on an upward trajectory. Biotech companies in Switzerland are heavily invested in developing new cancer treatments and immunotherapies, with pharma giants Novartis and Roche leading this space. Switzerland is also a hub for gene and cell therapy development and contributes to research on therapies targeting the aging process and age-related diseases, exemplified by Rejuveron Life Sciences’ impressive portfolio in the field. This article in Labiotech explores eighteen biotech companies based in Switzerland worth keeping an eye on: https://lnkd.in/ehnKdaEx #Switzerland #Biotech #Talent

𝐀𝐜𝐜𝐞𝐥𝐞𝐫𝐚𝐭𝐢𝐧𝐠 𝐭𝐡𝐞 𝐃𝐫𝐮𝐠 𝐃𝐞𝐯𝐞𝐥𝐨𝐩𝐦𝐞𝐧𝐭 𝐏𝐫𝐨𝐜𝐞𝐬𝐬 This insightful article is featured in "𝐏𝐡𝐚𝐫𝐦𝐚 𝐅𝐨𝐜𝐮𝐬 𝐄𝐮𝐫𝐨𝐩𝐞 𝐌𝐚𝐠𝐚𝐳𝐢𝐧𝐞 𝐈𝐬𝐬𝐮𝐞 𝟎𝟒." The human #immunesystem ability to scrutinize cells at a molecular level is nothing short of extraordinary. It can detect changes signaling the transformation from a normal cell to a rapidly multiplying cancer cell. This intricate mechanism involves presenting every intracellular protein on the cell surface for immune surveillance, allowing 𝐜𝐲𝐭𝐨𝐭𝐨𝐱𝐢𝐜 𝐓-𝐜𝐞𝐥𝐥𝐬 to recognize and eliminate transformed tumor cells. However, targeting pHLA complexes in cancer immunotherapy poses significant challenges. The development of 𝐛𝐢-𝐬𝐩𝐞𝐜𝐢𝐟𝐢𝐜 𝐓-𝐜𝐞𝐥𝐥 𝐞𝐧𝐠𝐚𝐠𝐞𝐫𝐬 (𝐓𝐂𝐄𝐬) requires precise targeting of cancer-specific 𝐩𝐇𝐋𝐀 complexes to avoid off-target effects and severe toxicity. By engineering two distinct monoclonal antibodies into a single bi-specific antibody, we aim to create a manufacturable, stable, and soluble compound for medical applications. Learn more in this insightful article by Mena Abdelsayed, Ph.D., Kyriakos Kachrimanis, and Joerg Birkenfeld. 🔗 𝐑𝐞𝐚𝐝 𝐭𝐡𝐞 𝐟𝐮𝐥𝐥 𝐚𝐫𝐭𝐢𝐜𝐥𝐞: https://lnkd.in/ettkr9Sp 🔗 𝐃𝐨𝐰𝐧𝐥𝐨𝐚𝐝 𝐭𝐡𝐞 𝐞-𝐛𝐨𝐨𝐤 𝐧𝐨𝐰: https://lnkd.in/gv7R4SPi #DrugDevelopment #CancerResearch #Immunotherapy #BiSpecificAntibodies #TCellEngagers #PrecisionMedicine #AIinHealthcare #BiomedicalEngineering #ClinicalTrials #PharmaceuticalInnovation #Biotech #Oncology #HealthcareTechnology #MedicalResearch #Pharmaceuticals

🚨 Breaking News in Biotech 🚨 Aptadir Therapeutics, a Milan-based biotech company, has raised $1.6M in Pre-Seed funding! 💰 This funding, provided by Extend, will drive the development of RNA inhibitor-based therapeutics targeting intractable cancers and genetic conditions. 🧬 The focus? Aptadir Ce-49, their lead asset, is set to revolutionize treatment for myelodysplastic neoplasms (MDS)—a blood cancer that often progresses to acute myeloid leukemia (AML). 🩸 Why It Matters: • Founded by top experts including Dr. Annalisa Di Ruscio and Dr. Vittorio De Franciscis, Aptadir is tapping into the oncology and rare disease fields. 🌐 • Their innovative platform can re-establish gene pathway functionality, targeting specific suppressed genes in cancers and genetic disorders. 🔬 The company plans to take Aptadir Ce-49 into the clinic by the end of 2025, marking a huge step toward more effective cancer treatments. 🎯 Biotech is evolving fast – are you keeping up? 🚀 📢 Stay tuned to Future Techly for the latest updates on this groundbreaking initiative and the latest in tech and business! 💥 Source: FinSMEs #Biotech #CancerResearch #RNAtherapeutics #Innovation #Funding #Healthcare #MDS #AML #Aptadir #FutureTechly

Clinical Trials Market to Grow $73.2 Billion by 2028 Download Sample PDF Report-https://lnkd.in/dTiYUy2a The global clinical trials market in terms of revenue was estimated to be worth $48.2 billion in 2023 and is poised to reach $73.2 billion by 2028, growing at a CAGR of 8.7% from 2023 to 2028. Companies Working in the Market Intelligencia AI Genome Medical     Medrio Viridian Therapeutics, Inc. CytoSorbents Corporation    CenExel Southern Research Sarah Cannon Cancer Network   Beaufort CRO  QPS Holdings, LLC The IMA Group  Fight Cancer Global      IGM Biosciences, Inc. Xencor M3 Wake Research     Aster Insights KV CLINICAL RESEARCH PVT LTD( Site Management Organization)      ProSciento, Inc.   Artiva Biotherapeutics    Reify Health Lindus Health     Ludwig Cancer Research Indica Labs QuickSTAT     Maravai LifeSciences  OmniComm Systems Virtual Incision The Geneva Foundation XenoTech, A BioIVT Company   Cognitive Research Corporation  Tasso, Inc. Andelyn Biosciences Hawthorne Effect, Inc. MedSource (now Ergomed) Fractyl Health Amarex Clinical Research, LLC, an NSF company Mercury Candel Therapeutics    DrugDev Microbiome Labs

Today is World Cancer Day, and here at Orchestra, we believe that the great strides needed to #BeatCancer is not only driven by pioneering medical breakthroughs but more importantly by collaborative efforts by innovative companies, patient advocacy teams, healthcare communities, governmental and not-for-profit agencies all working together in accelerating all modalities to curing cancer. We are truly dedicated to helping our partners move rapidly in the development and regulatory approvals of precision and personalized medicine in diverse areas including radiopharmaceutical therapies, cell and gene therapies, biologics and mRNA vaccines. Our patient-focused teams are committed to working very hard with our partners in groundbreaking efforts to make treatments more effective, more readily accessible and provide a better survival rate. Together, we are reimagining a future where the fight against cancer is stronger than ever before. #Worldcancerday #OrchestraLifeSciences #OLS #nuclearmedicine #CellandGeneTherapies #Clinicaltrials #radiopharmaceuticals #CancerReasearch #HealthcareInnovation #Closethecaregap #SNMMI #ASCO 

New Class of Drugs Discovered That May Work Against Cancer as Off-label Use A novel technology that can predict drug efficacy for individual non-responder cancer patient has been developed, offering new opportunities to tackle this devastating disease. The new assay overcomes the existing precision oncology testing workup that the currently available biomarker testing is failing to address. With this significant breakthrough, PGA (Patient-derived Gene expression-informed Anticancer drug efficacy) has the potential to address a major unmet need in the fight against cancer. Non-responder population is particularly difficult to benefit from targeted therapy because they are lacking actionable mutations that are specifically targeted by the targeted drugs. Most significantly, the mode of targeted therapy action suggests that evolving drug resistance is highly likely. Treatment options for progressive disease continue to dwindle as mortality rates are rising, with some estimated survival rates reaching only 20-30% for invasive tumors. The movement towards non-responder population is a new development, and one that can be facilitated by PGA that can rapidly identify potentially effective drugs for these individuals. Given that PGA-recommended drugs are already being approved or tested in clinical trials, the future looks promising, with the possibility of an approved drug class being finally on the horizon for invasive cancers as off-label usage. #opportunities #strategy #programming #design #team #research #data #health #development #collaboration #projects #testing #immunotherapy #cancer #technology #biotechnology #healthcare #medicine #oncology #precisionmedicine #liquidbiopsy #rna #dna #venturecapital #startup #immunooncology #tcells #innovation #growth #tech #lifesciences #biopharma #oncodxrx

𝐴𝑐𝑐𝑜𝑟𝑑𝑖𝑛𝑔 𝑡𝑜 𝑾𝑯𝑶, 𝑡ℎ𝑒 𝑔𝑙𝑜𝑏𝑎𝑙 𝑖𝑛𝑐𝑖𝑑𝑒𝑛𝑐𝑒 𝑜𝑓 𝑐𝑎𝑛𝑐𝑒𝑟 𝑖𝑠 𝑝𝑟𝑜𝑗𝑒𝑐𝑡𝑒𝑑 𝑡𝑜 𝑒𝑥𝑐𝑒𝑒𝑑 𝟑𝟓 𝒎𝒊𝒍𝒍𝒊𝒐𝒏 𝑛𝑒𝑤 𝑐𝑎𝑠𝑒𝑠 𝑏𝑦 𝟐𝟎𝟓𝟎, 𝑎 𝑠𝑖𝑔𝑛𝑖𝑓𝑖𝑐𝑎𝑛𝑡 𝑖𝑛𝑐𝑟𝑒𝑎𝑠𝑒 𝑓𝑟𝑜𝑚 𝑡ℎ𝑒 𝑒𝑠𝑡𝑖𝑚𝑎𝑡𝑒𝑑 𝟐𝟎 𝒎𝒊𝒍𝒍𝒊𝒐𝒏 𝑐𝑎𝑠𝑒𝑠 𝑖𝑛 𝟐𝟎𝟐𝟐. In this regard, RNA interference (RNAi) drug delivery has emerged as a promising strategy in cancer therapy. It utilizes nanotechnology to deliver RNA molecules that can silence specific genes implicated in tumor growth. Global initiatives are also advancing RNAi drug delivery technologies for cancer treatment. Organizations such as the 𝐍𝐚𝐭𝐢𝐨𝐧𝐚𝐥 𝐂𝐚𝐧𝐜𝐞𝐫 𝐈𝐧𝐬𝐭𝐢𝐭𝐮𝐭𝐞 (𝐍𝐂𝐈) in 𝐭𝐡𝐞 𝐔𝐧𝐢𝐭𝐞𝐝 𝐒𝐭𝐚𝐭𝐞𝐬 are spearheading research and development efforts in this field. Additionally, collaborations between academic institutions, pharmaceutical companies, and regulatory bodies are pivotal in accelerating the translation of RNAi research into clinical practice. Initiatives like those supported by the 𝐈𝐧𝐧𝐨𝐯𝐚𝐭𝐢𝐯𝐞 𝐌𝐞𝐝𝐢𝐜𝐢𝐧𝐞𝐬 𝐈𝐧𝐢𝐭𝐢𝐚𝐭𝐢𝐯𝐞 (𝐈𝐌𝐈) in 𝐄𝐮𝐫𝐨𝐩𝐞 foster interdisciplinary partnerships to address scientific and regulatory challenges comprehensively. In line with this focus, our recent blog, ‘𝐓𝐚𝐫𝐠𝐞𝐭𝐞𝐝 𝐓𝐡𝐞𝐫𝐚𝐩𝐢𝐞𝐬 & 𝐅𝐮𝐭𝐮𝐫𝐞 𝐃𝐢𝐫𝐞𝐜𝐭𝐢𝐯𝐞𝐬: 𝐑𝐍𝐀𝐢 𝐃𝐫𝐮𝐠 𝐃𝐞𝐥𝐢𝐯𝐞𝐫𝐲 𝐌𝐚𝐫𝐤𝐞𝐭’, highlights innovations in pharmaceuticals that leverage nanotechnology for precise cancer therapies with minimal side effects. Check here: https://lnkd.in/dCve5Zyv So, let's delve into RNAi's role in revolutionizing cancer research by targeting specific genes involved in tumor progression through our blog. Looking forward to hearing your thoughts in the comments below! . . . Arbutus Biopharma Corporation Arcturus Therapeutics Mirimus Sirnaomics #rnai #rnainterference #drugdelivery #healthcare #biotechnology #cancertherapy #nanotechnology #marketgrowth #inkwoodresearch